How big is Xilio Therapeutics, Inc.?

As of Jun 18, Xilio Therapeutics, Inc. has a market capitalization of 34.44 million and reported net sales of 9.27 million with a net profit of -54.31 million over the last four quarters.

Market Cap: As of Jun 18, Xilio Therapeutics, Inc. has a market capitalization of 34.44 million, categorized as a Micro Cap.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Xilio Therapeutics, Inc. reported net sales of 9.27 million and a net profit of -54.31 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 17.60 million and total assets of 71.08 million.

What does Xilio Therapeutics, Inc. do?

Xilio Therapeutics, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $3 million and a net loss of $13 million as of March 2025. The company has a market cap of $34.44 million and does not pay dividends.

Overview: <BR>Xilio Therapeutics, Inc. operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 3 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -13 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 34.44 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -8.21 <BR>Return on Equity: -507.61% <BR>Price to Book: 3.22<BR><BR>Contact Details: <BR>Details: No Company Details Available <BR>Registrar Address: Not available.

Should I buy, sell or hold Xilio Therapeutics, Inc.?

Is Xilio Therapeutics, Inc. overvalued or undervalued?

As of August 8, 2024, Xilio Therapeutics, Inc. is considered risky and overvalued due to a high Price to Book Value of 3.39, a low EV to EBIT of 0.91, a troubling ROE of -507.61%, and significant underperformance with a year-to-date return of -20.06% compared to the S&P 500's 12.22%.

As of 8 August 2024, the valuation grade for Xilio Therapeutics, Inc. has moved from does not qualify to risky, indicating a shift in perception regarding its financial health. The company appears to be overvalued given its high Price to Book Value of 3.39 and low EV to EBIT of 0.91, alongside a troubling ROE of -507.61%. Compared to peers, Xilio's valuation metrics are concerning; for instance, ADC Therapeutics SA has a more negative EV to EBITDA of -4.7475, while Kinnate Biopharma, Inc. shows a more favorable EV to EBITDA of 0.2381.<BR><BR>In terms of stock performance, Xilio has underperformed significantly against the S&P 500, with a year-to-date return of -20.06% compared to the index's 12.22%. This stark contrast reinforces the notion that the stock may be overvalued in the current market context.

Is Xilio Therapeutics, Inc. technically bullish or bearish?

As of September 12, 2025, Xilio Therapeutics, Inc. shows a neutral trend with mixed technical signals, having outperformed the S&P 500 recently but with significant negative year-to-date and one-year returns, suggesting a cautious investment approach.

As of 12 September 2025, the technical trend for Xilio Therapeutics, Inc. has changed from mildly bearish to sideways. The current stance is neutral, with mixed signals across various indicators. The MACD is mildly bullish on both weekly and monthly time frames, while the RSI shows bearish conditions on the weekly but no signal on the monthly. Bollinger Bands indicate bullishness weekly but mildly bearish monthly. Moving averages are mildly bearish on the daily, and the KST is mildly bullish weekly but bearish monthly. Dow Theory shows no trend weekly and mildly bearish monthly, while OBV is bullish monthly but shows no trend weekly.<BR><BR>In terms of performance, the stock has outperformed the S&P 500 over the past week and month, with returns of 4.62% and 7.98% compared to 1.05% and 2.33%, respectively. However, year-to-date and one-year returns are significantly negative at -20.06% and -6.3%, contrasting sharply with the S&P 500's positive returns of 12.22% and 17.14%. Overall, the technical indicators suggest a cautious approach given the mixed signals and recent performance.